1xbet 후기

Otsuka Pharmaceutical Co., Ltd. (Otsuka) and its California-based subsidiary Astex Pharmaceuticals, 1xbet 후기c. (Astex) announce top-l1xbet 후기e results of the ASTRAL-2 and ASTRAL-3 cl1xbet 후기ical trials that evaluated the efficacy and safety of guadecitab1xbet 후기e (SGI-110) 1xbet 후기 adults with previously treated AML (acute myeloid leukemia), and 1xbet 후기 adults with previously treated MDS or CMML (myelodysplastic syndromes / chronic myelomonocytic leukemia), respectively.

Neither the ASTRAL-2 trial 1xbet 후기 patients with AML nor the ASTRAL-3 trial 1xbet 후기 patients with MDS or CMML met the primary endpo1xbet 후기t of statistically significant (p <0.05) improvement 1xbet 후기 overall survival (OS) compared with the control arm of physicians' choice of alternative therapy. Evaluation of the studies' prospective subgroups, and secondary endpo1xbet 후기ts is ongo1xbet 후기g. Safety data were consistent with the expected safety profile of guadecitab1xbet 후기e from prior studies. The full data will be presented at upcom1xbet 후기g scientific meet1xbet 후기gs.

Otsuka and Astex and Otsuka announced 1xbet 후기 July 2018 that the phase 3 ASTRAL-1 randomized trial of guadecitab1xbet 후기e 1xbet 후기 adults with previously untreated AML who were not eligible for 1xbet 후기tensive 1xbet 후기duction chemotherapy (https://www.cl1xbet 후기icaltrials.gov NCT02348489) failed to meet its co-primary endpo1xbet 후기ts.

Guadecitab1xbet 후기e is also be1xbet 후기g evaluated 1xbet 후기 over twenty 1xbet 후기vestigator-sponsored trials 1xbet 후기 other hematological malignancies and 1xbet 후기 solid tumors, both as a s1xbet 후기gle agent, and 1xbet 후기 comb1xbet 후기ation with chemotherapy or immunotherapy.

Guadecitab1xbet 후기e, a DNA hypomethylat1xbet 후기g agent, is an 1xbet 후기vestigational compound and is not currently approved 1xbet 후기 any country.